Comparative Pharmacology
Head-to-head clinical analysis: FUNDUSCEIN 25 versus PORCINE SECRETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUNDUSCEIN 25 versus PORCINE SECRETIN.
FUNDUSCEIN-25 vs PORCINE SECRETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorescein sodium absorbs blue light (465–490 nm) and emits yellow-green fluorescence (520–530 nm), allowing visualization of retinal and choroidal vasculature. It binds to serum proteins and leaks from abnormal blood vessels, highlighting areas of neovascularization or edema.
Stimulates exocrine pancreatic secretion by acting on secretin receptors on pancreatic ductal cells, increasing bicarbonate and water secretion. Also stimulates bile and gastric acid secretion.
0.5 mL of FUNDUSCEIN-25 (25 mg/mL) administered intravenously as a single bolus injection over 5-10 seconds.
0.2 mcg/kg intravenous bolus over 1 minute, maximum 20 mcg.
None Documented
None Documented
Terminal elimination half-life is approximately 26 minutes in adults (range 20–30 minutes). Clinical context: Rapid clearance allows repeated injections within 30–60 minutes if needed.
The terminal elimination half-life is approximately 4-6 minutes, reflecting rapid degradation by plasma proteases; this short half-life limits its systemic duration of action and necessitates continuous infusion for sustained secretory testing.
Primarily renal elimination of unchanged fluorescein and its glucuronide conjugate (80% within 24 hours). Biliary/fecal excretion accounts for <5%.
Primarily renal, with over 90% of the administered dose eliminated via glomerular filtration and tubular reabsorption; fecal and biliary excretion are negligible.
Category C
Category C
Diagnostic Agent
Diagnostic Agent